Copyright
©The Author(s) 2021.
World J Clin Oncol. Jan 24, 2021; 12(1): 31-42
Published online Jan 24, 2021. doi: 10.5306/wjco.v12.i1.31
Published online Jan 24, 2021. doi: 10.5306/wjco.v12.i1.31
Table 3 Priorities for telemedicine
Medium priority | Low priority | Comments |
(1) During the pandemic, most patients could be evaluated using telemedicine (if feasible) (Yes: 100%, No: 0%); and (2) BC patients who can be evaluated with telemedicine: (a) Patients completing neoadjuvant chemotherapy and waiting for surgery (Yes: 89%, No: 11%); (b) Patients eligible for radiotherapy (Yes: 89%, Abst: 11%); and (c) Patients receiving oral chemotherapy or endocrine therapy + targeted therapy (Yes: 78%, No: 22%) | Patients can be evaluated with telemedicine (including after pandemic is over): (a) Routine evaluations in patients who are in periodic controls (observation) or endocrine therapy (Yes: 78%, No: 22%); (b) Survivorship follow-up (Yes: 100%, No: 0%); (c) Psychological visits (Yes: 100%, No: 0%); and (d) New diagnosis of non-invasive BC (Yes: 100%, No: 0%) | (1) During follow-up of patients with high-risk of recurrence, an in-person visit can be assessed according to evolution (if necessary); and (2) In some oncological centers, it is possible to evaluate in-person oral treatments of continuing patients (including whom with adjuvant therapy) |
- Citation: Valencia GA, Neciosup S, Gómez HL, Benites MDP, Falcón S, Moron D, Veliz K, Maldonado M, Auqui R. Adaptation of international coronavirus disease 2019 and breast cancer guidelines to local context. World J Clin Oncol 2021; 12(1): 31-42
- URL: https://www.wjgnet.com/2218-4333/full/v12/i1/31.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i1.31